NICE has recommended two of GW Pharma's cannabis-based medicines, the first time that medicines derived from the plant have been recommended for NHS funding.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh